QURE Deadline: Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Rosen Law Firm, a prominent global investor rights law firm, has issued a reminder to shareholders of uniQure N.V. (NASDAQ: QURE) regarding a class action lawsuit. Filed on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, the lawsuit alleges that uniQure misled investors about its business operations and key regulatory approvals.

Particularly, the lawsuit claims that the company did not fully disclose that the design of its pivotal study—evaluating its leading drug candidate for Huntington’s Disease—was not fully approved by the U.S. Food and Drug Administration (FDA). Additionally, it is alleged that uniQure downplayed the possibility of delaying its Biologics License Application (BLA) due to the need for further studies, thereby misrepresenting the company's business prospects and operations.

As a result of these misrepresentations, shareholders who suffered losses exceeding $100,000 are urged to contact Rosen Law Firm to understand their legal rights and potential recovery options. Potential lead plaintiffs must file motions with the court by April 13, 2026. Rosen Law Firm operates on a contingency fee basis, meaning shareholders incur no legal fees or expenses unless a recovery is achieved.

Rosen Law Firm is distinguished for its commitment to shareholder rights litigation, having recovered more than $1 billion for shareholders since its establishment. The firm emphasizes accountability for corporate executives and aims to strengthen corporate governance.

For those interested in more information about becoming part of the class action or understanding their rights, the firm encourages reaching out via their website or by phone. As the situation unfolds, investors can follow the latest updates on various social media platforms.

As a financial analyst, it's essential to consider the implications of legal issues on stock performance, particularly in cases like uniQure N.V. (NASDAQ: QURE), which is currently embroiled in a class action lawsuit. The allegations pertain to misleading information regarding the company's pivotal study related to Huntington’s Disease, raising concerns about regulatory compliance and the company's ability to operate transparently.

The lawsuit claims that uniQure misrepresented its clinical study design and downplayed potential delays in its Biologics License Application (BLA) process. Such allegations can impact investor confidence significantly. When investors realize that the company’s previous projections were overly optimistic or based on unapproved methodologies, it can lead to a sell-off, as seen in many similar cases across the biotech sector.

For existing shareholders, this is a pivotal moment. If you've sustained losses exceeding $100,000, it may be prudent to explore participation in the class action being organized by the Rosen Law Firm. Engaging with this legal avenue helps ensure that your voice is heard and that a unified shareholder front stands against potentially negligent conduct by company executives.

From a market perspective, investors should remain cautious. The resolution of this legal situation could lead to volatility in share prices, especially if additional negative disclosures emerge or if the FDA imposes further restrictions on uniQure's operations.

For those considering entering the market, it may be wise to wait for clarity regarding the lawsuit's outcome or any official responses from uniQure regarding the allegations. A more stable opportunity could arise as the company resolves these legal matters and works on restoring investor confidence. In summary, weigh your options carefully, and consider both the risks and potential rewards in this dynamic environment.